The DOI matches its Crossref record; 558 of the 558 references it cites were found in a registry or an index.
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 558
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192
Self-citationCarlsson, T., Carta, M., Winkler, C., Björklund, A., & Kirik, D. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2079-07.2007 · Cited by 191
Ding, Y., Won, L., Britt, J. P., Lim, S. A. O., McGehee, D. S., & Kang, U. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006511108 · Cited by 188
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum, J. M. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198713030-00002 · Cited by 187
Chemical anatomy of primate basal ganglia
Parent, A. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00001-c · Cited by 187
Arai, R., Karasawa, N., Geffard, M., & Nagatsu, I. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11817-g · Cited by 185
Lastres‐Becker, I., Cebeira, M., de Ceballos, M. L., Zeng, B. ‐., Jenner, P., Ramos, J. A., & Fernández‐Ruiz, J. J. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01812.x · Cited by 185
Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys
Blanchet, P. J., Konitsiotis, S., & Chase, T. N. (1998) · Movement Disorders · doi:10.1002/mds.870130507 · Cited by 185
Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease
Hauser, R. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1756 · Cited by 183
Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated Monkeys
Gomez-Mancilla, B., & Bedard, P. J. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199310000-00004 · Cited by 181
Structural insights into adrenergic receptor function and pharmacology
Kobilka, B. K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.005 · Cited by 181
Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons
Testa, C. M., Standaert, D. G., Landwehrmeyer, G. B., Penney, J. B., & Young, A. B. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903540207 · Cited by 181
Lu, H.-C., Gonzalez, E., & Crair, M. C. (2001) · Neuron · doi:10.1016/s0896-6273(01)00501-3 · Cited by 180
Newman-Tancredi, A., Cussac, D., Audinot, V., Nicolas, J.-P., De Ceuninck, F., Boutin, J.-A., & Millan, M. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039875 · Cited by 179
Piccini, P., Weeks, R. A., & Brooks, D. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420508 · Cited by 177
AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23616 · Cited by 175
Clinical Pharmacokinetics of Ropinirole
Kaye, C. M., & Nicholls, B. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00001 · Cited by 175
Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W., & Cenci, M. A. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.150425 · Cited by 172
Adham, N., Romanienko, P., Hartig, P., Weinshank, R. L., & Branchek, T. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08798-x · Cited by 171
Lucas, G., & Spampinato, U. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740693.x · Cited by 170
Mesulam, M. ‐., Mash, D., Hersh, L., Bothwell, M., & Geula, C. (1992) · Journal of Comparative Neurology · doi:10.1002/cne.903230209 · Cited by 169
Filion, M. (1979) · Brain Research · doi:10.1016/0006-8993(79)90704-2 · Cited by 168
Quock, R. M., Burkey, T. H., Varga, E. V., Hosohata, Y., Hosohata, K., Cowell, S. M., Slate, C. A., Ehlert, F. J., Roeske, W. R., & Yamamura, H. I. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01416-9 · Cited by 166
Di Monte, D. A., McCormack, A., Petzinger, G., Janson, A. M., Quik, M., & Langston, W. J. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<459::aid-mds1006>3.0.co;2-3 · Cited by 165
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders
Hahnen, E., Hauke, J., Tränkle, C., Eyüpoglu, I. Y., Wirth, B., & Blümcke, I. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.169 · Cited by 165
Fox, S. H., Henry, B., Hill, M., Crossman, A., & Brotchie, J. (2002) · Movement Disorders · doi:10.1002/mds.10289 · Cited by 164
Self-citationCortical motor overactivation in parkinsonian patients with L-dopa- induced peak-dose dyskinesia
Rascol, O. (1998) · Brain · doi:10.1093/brain/121.3.527 · Cited by 164
Ottosson, D. R., Iderberg, H., Li, Q., Dekundy, A., Zhang, J., Li, H., Baishen, R., Danysz, W., Bézard, E., & Cenci, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.001 · Cited by 162
Levodopa‐dyskinesia incidence by age of Parkinson's disease onset
Kumar, N., Van Gerpen, J. A., Bower, J. H., & Ahlskog, J. E. (2005) · Movement Disorders · doi:10.1002/mds.20360 · Cited by 162
Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy
Rinne, J. O., Anichtchik, O. V., Eriksson, K. S., Kaslin, J., Tuomisto, L., Kalimo, H., Röyttä, M., & Panula, P. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00871.x · Cited by 162
Quock, R. M., Burkey, T. H., Varga, E. V., Hosohata, Y., Hosohata, K., Cowell, S. M., Slate, C. A., Ehlert, F. J., Roeske, W. R., & Yamamura, H. I. (1999) · PubMed · Cited by 162
Development of dyskinesias in a 5‐year trial of ropinirole and L ‐dopa
Rascol, O., Brooks, D. J., Korczyn, A. D., Deyn, P. P. D., Clarke, C. E., Lang, A. E., & Abdalla, M. (2006) · Movement Disorders · doi:10.1002/mds.20988 · Cited by 161
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh, K. C., August, T. F., Bush, D., Lasseter, K. C., Musson, D. G., Schwartz, S. E., Smith, M. E., & Titus, D. C. (1989) · PubMed · Cited by 161
Savola, J., Hill, M. P., Engström, M., Merivuori, H., Wurster, S., McGuire, S. G., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10464 · Cited by 159
Self-citationVila, M., Levy, R., Herrero, M.-T., Ruberg, M., Faucheux, B., Obeso, J. A., Agid, Y., & Hirsch, E. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00765.1997 · Cited by 158
Corvol, J.-C., Muriel, M.-P., Valjent, E., Féger, J., Hanoun, N., Girault, J.-A., Hirsch, E. C., & Hervé, D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0676-04.2004 · Cited by 158
Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z. L., Woodward, R. M., & Chase, T. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35003-7 · Cited by 158
Fasano, S., Bézard, E., D'Antoni, A., Francardo, V., Indrigo, M. T., Li, Q., Doveró, S., Cerovic, M., Cenci, M. A., & Brambilla, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012071107 · Cited by 157
COURT, J. A., Piggott, M. A., Lloyd, S. R., Cookson, N., Ballard, C. G., McKeith, I. G., Perry, R. H., & Perry, E. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00071-3 · Cited by 157
Continuous dopamine-receptor stimulation in advanced Parkinson's disease
Nutt, J. G., Obeso, J. A., & Stocchi, F. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00029-x · Cited by 157
Arai, R., Karasawa, N., Geffard, M., Nagatsu, T., & Nagatsu, I. (1994) · Brain Research · doi:10.1016/0006-8993(94)91511-3 · Cited by 156
Dotto, P. D., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L. V., Chase, T. N., & Bonuccelli, U. (2001) · Movement Disorders · doi:10.1002/mds.1112 · Cited by 153
Oh, J. D., Russell, D., Vaughan, C. L., & Chase, T. N. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01049-x · Cited by 153
Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis
Wolters, E. C., Hurwitz, T. A., Mak, E., Teal, P. A., Peppard, F. R., Remick, R. A., Calne, S. M., & Calne, D. B. (1990) · Neurology · doi:10.1212/wnl.40.5.832 · Cited by 153
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
Muenter, M. D., Sharpless, N. S., Tyce, G. M., & Darley, F. L. (1977) · PubMed · Cited by 151
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease
Scheller, D., Ullmer, C., Berkels, R., Gwarek, M., & Lübbert, H. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0341-4 · Cited by 151
Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., & for the Amantadine Study Group (2010) · PLoS ONE · doi:10.1371/journal.pone.0015298 · Cited by 151
Robelet, S., Melon, C., Guillet, B. A., Salin, P., & Goff, L. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03591.x · Cited by 151
Ohlin, K. E., Francardo, V., Lindgren, H. S., Sillivan, S. E., O’Sullivan, S. S., Luksik, A. S., Vassoler, F. M., Lees, A. J., Konradi, C. L., & Cenci, M. A. (2011) · Brain · doi:10.1093/brain/awr165 · Cited by 150
Meissner, W. G., Ravenscroft, P., Reese, R., Harnack, D., Morgenstern, R., Kupsch, A. R., Klitgaard, H., Bioulac, B. H., Gross, C. E., Bézard, E., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.009 · Cited by 150
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Rascol, O., Arnulf, I., Paul, H. P., Brefel‐Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B.-P. W., Fabre, N., et al. (2001) · Movement Disorders · doi:10.1002/mds.1143 · Cited by 149
Rascol, O., Nutt, J. G., Blin, O. J., Goetz, C. G., Trugman, J. M., Soubrouillard, C., Carter, J. H., Currie, L. J., Fabre, N., Thalamas, C., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.249 · Cited by 149
Deng, Y., Lei, W., & Reiner, A. J. (2006) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2006.07.001 · Cited by 148
Mauborgne, A., Javoy-Agid, F., Legrand, J. C., Agid, Y., & Cesselin, F. (1983) · Brain Research · doi:10.1016/0006-8993(83)90403-1 · Cited by 148
Morelli, M., Paolo, T. D., Wardas, J., Calon, F., Xiao, D., & Schwarzschild, M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.001 · Cited by 146
An Altered Histaminergic Innervation of the Substantia Nigra in Parkinson's Disease
Anichtchik, O. V., Rinne, J. O., Kalimo, H., & Panula, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7362 · Cited by 146
Hirano, S., Asanuma, K., Ma, Y., Tang, C., Feigin, A., DHAWAN, V. M., Carbon, M., & Eidelberg, D. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0582-08.2008 · Cited by 145
Andersson, M., Konradi, C. L., & Cenci, M. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09930.2001 · Cited by 145
Rascol, O., Sabatini, U., Chollet, F., Fabre, N., Sénard, J., Montastruc, J., Celsis, P., Marc-Vergnes, J. P., & Rascol, A. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.5.567 · Cited by 143
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism
Maccarrone, M., Gubellini, P., Bari, M., Picconi, B., Battista, N., Centonze, D., Bernardi, G., Finazzi‐Agrò, A., & Calabresi, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01759.x · Cited by 143
Ahmed, M. R., Berthet, A., Бычков, Э. Р., Porras, G., Li, Q., Bioulac, B. H., Carl, Y. T., Bloch, B., Kook, S., Aubert, I., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000664 · Cited by 143
Blanchet, P. J., Calon, F., Martel, J.-C., Bédard, P. J., Paolo, T. D., Walters, R. R., & Piercey, M. F. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24503-7 · Cited by 142
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141
Henry, B. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00064-5 · Cited by 141
Berthet, A., Porras, G., Doudnikoff, É., Stark, H., Cador, M., Bézard, E., & Bloch, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5884-08.2009 · Cited by 140
Picconi, B., Bagetta, V., Ghiglieri, V., Paillé, V., Filippo, M. D., Pendolino, V., Tozzi, A., Giampà, C., Fusco, F. R., Sgobio, C., et al. (2010) · Brain · doi:10.1093/brain/awq342 · Cited by 140
GABAergic interneurons in human subthalamic nucleus
Lévesque, J., & Parent, A. (2005) · Movement Disorders · doi:10.1002/mds.20374 · Cited by 140
Herrero, M. T., Augood, S. J., Hirsch, É. C., Javoy-Agid, F., Luquín, M. R., Agid, Y., Obeso, J. A., & Emson, P. C. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00120-8 · Cited by 139
Johnston, T. H., Fox, S. H., McIldowie, M. J., Piggott, M., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166629 · Cited by 137
Self-citationSmith, A. J., Alder, L., Silk, J. D., ADKINS, C. E., Fletcher, A. E., Scales, T. M. E., Kerby, J., Marshall, G. R., Wafford, K. A., McKernan, R. M., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.5.1108 · Cited by 137
Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients
Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., Hashimoto, M., Ishibashi, K., Oda, K., Sakata, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017338 · Cited by 136
Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
Guigoni, C., Doudnikoff, É., Li, Q., Bloch, B., & Bézard, E. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.02.001 · Cited by 136
Bordet, R., Ridray, S., Schwartz, J.-C., & Sokoloff, P. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00089.x · Cited by 135
Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution
Heckers, S., Geula, C., & Mesulam, M. M. (1992) · The Journal of Comparative Neurology · doi:10.1002/cne.903250107 · Cited by 134
Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., & Landen, J. W. (2008) · Movement Disorders · doi:10.1002/mds.22169 · Cited by 133
Bibbiani, F., Oh, J. D., Kielaitė, A., Collins, M. A., Smith, C., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.017 · Cited by 133
Parkin, S., Gregory, R., Scott, R., Bain, P., Silburn, P., Hall, B., Boyle, R., Joint, C., & Aziz, T. (2002) · Movement Disorders · doi:10.1002/mds.10186 · Cited by 133
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Maneuf, Y. P., Nash, J. E., Crossman, A. R., & Brotchie, J. M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00326-3 · Cited by 132
Self-citationWestin, J. E., Lindgren, H. S., Gardi, J. E., Nyengaard, J. R., Brundin, P., Mohapel, P., & Cenci, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0944-06.2006 · Cited by 132
Henry, B., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7727 · Cited by 132
Self-citationSerotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Cenci, M. A., Tranberg, A., Andersson, M., & Hilbertson, A. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00294-8 · Cited by 131
Gold, S. J., Hoang, C. V., Potts, B. W., Porras, G., Pioli, E. Y., Kim, K. W., Nadjar, A., Qin, C., LaHoste, G. J., Li, Q., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4223-07.2007 · Cited by 129
Nadjar, A., Gerfen, C. R., & Bézard, E. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.09.013 · Cited by 129
Westin, J. E., Andersson, M., Lundblad, M., & Cenci, M. A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01743.x · Cited by 129
Maeda, T., Nagata, K., Yoshida, Y., & Kannari, K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.019 · Cited by 126
Serotoninergic innervation of the thalamus in the primate: An immunohistochemical study
Lavoie, B. A., & Parent, A. (1991) · The Journal of Comparative Neurology · doi:10.1002/cne.903120102 · Cited by 126
Santini, E., Sgambato, V., Li, Q., Savasta, M., Doveró, S., Fisone, G., & Bézard, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012322 · Cited by 125
Jaunarajs, K. L. E., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., & Bishop, C. (2009) · Synapse · doi:10.1002/syn.20630 · Cited by 124
Orthostatic Hypotension in Patients with Parkinson??s Disease: Pathophysiology and Management
Sénard, J., Brefel‐Courbon, C., Rascol, O., & Montastruc, J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118070-00003 · Cited by 124
p11 (S100A10) — an inducible adaptor protein that modulates neuronal functions
Svenningsson, P., & Greengard, P. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.001 · Cited by 123
Placebo influences on dyskinesia in Parkinson's disease
Goetz, C. G., LASKA, E. M., Hicking, C., Damier, P., Müller, T. H., Nutt, J. G., Olanow, C. W., Rascol, O., & Russ, H. (2008) · Movement Disorders · doi:10.1002/mds.21897 · Cited by 123
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
Bibbiani, F., Costantini, L. C., Patel, R., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.013 · Cited by 123
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
Samadi, P., Grégoire, L., Morissette, M., Calon, F., Tahar, A. H., Dridi, M., Bélanger, N., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.005 · Cited by 122
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
Picconi, B., Paillé, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H. S., Bernardi, G., Cenci, M. A., & Calabresi, P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.001 · Cited by 122
Julien, C., Berthiaume, L., Tahar, A. H., Rajput, A. H., Bédard, P. J., Paolo, T. D., Julien, P., & Calon, F. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.002 · Cited by 122
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
Metman, V. L., Dotto, D. P., Natté, R., van den Munckhof, P., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.51.1.203 · Cited by 122
Dupre, K. B., Ostock, C. Y., Jaunarajs, K. L. E., Button, T., Savage, L. M., Wolf, W. A., & Bishop, C. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.02.012 · Cited by 122
Hauser, R. A., Panisset, M., Abbruzzese, G., Mancione, L., Dronamraju, N., Kakarieka, A., & on behalf of the FIRST‐STEP Study Group (2008) · Movement Disorders · doi:10.1002/mds.22343 · Cited by 122
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients
Gancher, S. T., Nutt, J. G., & Woodward, W. R. (1987) · Neurology · doi:10.1212/wnl.37.6.940 · Cited by 121
Calon, F., Birdi, S., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.2.186 · Cited by 121
Bordia, T., Campos, C., Huang, L., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140897 · Cited by 120
Dopaminergic neurons intrinsic to the striatum
Huot, P., & Parent, A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04430.x · Cited by 120
Self-citationFox, S. H., Kellett, M., Moore, A. P., Crossman, A. R., & Brotchie, J. M. (2002) · Movement Disorders · doi:10.1002/mds.1280 · Cited by 120
Self-citationBarnum, C. J., Jaunarajs, K. L. E., Dupre, K. B., Blandino, P., Deak, T., & Bishop, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.016 · Cited by 119
Anichtchik, O. V., Peitsaro, N., Rinne, J. O., Kalimo, H., & Panula, P. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0413 · Cited by 118
Chronic high dose transdermal nicotine in Parkinson's disease: an open trial
Villafane, G., Césaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Houezec, J. L., Macquin‐Mavier, I., & Maison, P. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01949.x · Cited by 118
Zhang, X., Andrén, P. E., Greengard, P., & Svenningsson, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711839105 · Cited by 118
Steady‐State Pharmacokinetic Properties of Pramipexole in Healthy Volunteers
Wright, C. E., Sisson, T. L., Ichhpurani, A. K., & Peters, G. R. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04330.x · Cited by 117
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D. B., & Stoessl, A. J. (2004) · Brain · doi:10.1093/brain/awh102 · Cited by 117
Morin, N., Grégoire, L., Gomez‐Mancilla, B., Gasparini, F., & Paolo, T. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.024 · Cited by 116
Entacapone in the treatment of Parkinson's disease
Schrag, A. E. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70098-3 · Cited by 116
Iravani, M., Tayarani-Binazir, K. A., Chu, W. B., Jackson, M., & Jenner, P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110429 · Cited by 115
Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
Schapira, A. H. V., Barone, P., Hauser, R. A., Mizuno, Y., Rascol, O., Busse, M., Salin, L., Juhel, N., Poewe, W. H., & For the Pramipexole ER Studies Group (2011) · Neurology · doi:10.1212/wnl.0b013e31822affdb · Cited by 115
The Economic Impact of Parkinson???s Disease
Dodel, R. C., Singer, M., Köhne-Volland, R., Szucs, T. D., Rathay, B., Scholz, E., & Oertel, W. H. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814030-00006 · Cited by 113
Paradoxes of functional neurosurgery: Clues from basal ganglia recordings
Brown, P., & Eusébio, A. (2007) · Movement Disorders · doi:10.1002/mds.21796 · Cited by 113
Reddy, S., Factor, S. A., Molho, E., & Feustel, P. J. (2002) · Movement Disorders · doi:10.1002/mds.10176 · Cited by 113
Walking stability using harmonic ratios in Parkinson's disease
Lowry, K. A., Smiley‐Oyen, A. L., Carrel, A. J., & Kerr, J. P. (2008) · Movement Disorders · doi:10.1002/mds.22352 · Cited by 113
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2004) · Movement Disorders · doi:10.1002/mds.20317 · Cited by 113
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2005) · Movement Disorders · doi:10.1002/mds.20421 · Cited by 112
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
Troiano, A. R., de la Fuente‐Fernández, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T. J., & Stoessl, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000338631.73211.56 · Cited by 111
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA–induced dyskinesia
Subramaniam, S., Napolitano, F., Mealer, R. G., Kim, S., Errico, F., Barrow, R. K., Shahani, N., Tyagi, R., Snyder, S. H., & Usiello, A. (2011) · Nature Neuroscience · doi:10.1038/nn.2994 · Cited by 111
Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Movement Disorders · doi:10.1002/mds.10343 · Cited by 110
Damiano, A. M., Mordin, M., Willian, M. K., Snyder, C. F., LeWitt, P. A., Reyes, P. F., Richter, R., & Means, E. D. (2000) · Quality of Life Research · doi:10.1023/a:1008928321652 · Cited by 109
Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain
Hurley, M. J., Mash, D. C., & Jenner, P. G. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0033-7 · Cited by 109
Grégoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D. R., Vranesic, I., Sahasranaman, S., Gomez‐Mancilla, B., & Paolo, T. D. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.01.008 · Cited by 109
Kobylecki, C., Cenci, M. A., Crossman, A. R., & Ravenscroft, P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06776.x · Cited by 107
Zeng, B. ‐., Pearce, R. K. B., MacKenzie, G. M., & Jenner, P. G. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00988.x · Cited by 107
L -Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations
Pearce, R. K. B., Heikkilä, M., I.-B., L. X. E. N., & Jenner, P. G. (2001) · Psychopharmacology · doi:10.1007/s002130100733 · Cited by 107
Tel, B. C., Zeng, B. ‐., Cannizzaro, C., Pearce, R. K. B., Rose, S., & Jenner, P. G. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00535-3 · Cited by 107
Levodopa-induced dyskinesias are improved by fluoxetine
Durif, F., Vidailhet, M., Bonnet, A. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.10.1855 · Cited by 107
Berton, O., Guigoni, C., Li, Q., Bioulac, B. H., Aubert, I., Gross, C. E., Dileone, R., Nestler, E. J., & Bézard, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.005 · Cited by 106
Samadi, P., Grégoire, L., Rouillard, C., Bédard, P. J., Paolo, T. D., & Lévesque, D. (2006) · Annals of Neurology · doi:10.1002/ana.20738 · Cited by 105
Giorgi, M., D’Angelo, V., Esposito, Z., Nuccetelli, V., Sorge, R. P., Martorana, A., Stefani, A., Bernardi, G., & Sancesario, G. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06387.x · Cited by 105
Striatal histone modifications in models of levodopa‐induced dyskinesia
Nicholas, A. P., Lubin, F. D., Hallett, P. J., Vattem, P., Ravenscroft, P., Bézard, E., Zhou, S., Fox, S. H., Brotchie, J. M., Sweatt, J. D., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05417.x · Cited by 103
Self-citationLemay, S., Chouinard, S., Blanchet, P. J., Masson, H., Soland, V., Beuter, A. C., & Bédard, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00172-6 · Cited by 102
Fabian, C. J., Tilzer, L. L., & Sternson, L. A. (1981) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510020407 · Cited by 102
Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys
Boyce, S., Rupniak, N. M. J., Steventon, M. J., et al. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199010000-00006 · Cited by 101
Cao, X., Li, L., Hadcock, J. R., Iredale, P. A., Griffith, D. A., Menniti, F. S., Factor, S. A., Greenamyre, J. T., & Papa, S. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125666 · Cited by 101
Sammut, S., Dec, A. M., Mitchell, D., Linardakis, J., Ortigüela, M., & West, A. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300826 · Cited by 100
Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease
Fujita, M., Ichise, M., Zoghbi, S. S., Liow, J., Ghose, S., Vines, D. C., Sangare, J., Lu, J., Cropley, V., Iida, H., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20688 · Cited by 100
Visanji, N. P., Gómez-Ramírez, J., Johnston, T. H., Pires, D., Voon, V., Brotchie, J. M., & Fox, S. H. (2006) · Movement Disorders · doi:10.1002/mds.21073 · Cited by 100
Self-citationMetabotropic glutamate receptor type 5 in levodopa-induced motor complications
Ouattara, B., Grégoire, L., Morissette, M., Gasparini, F., Vranesic, I., Bilbe, G., Johns, D. R., Rajput, A. H., Hornykiewicz, O., Rajput, A. H., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.014 · Cited by 100
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
LeWitt, P., Hauser, R., Lu, M., Nicholas, A., Weiner, W., Coppard, N., Leinonen, M., & Savola, J. (2012) · Neurology · doi:10.1212/wnl.0b013e31825f0451 · Cited by 99
Grégoire, L., Samadi, P., Graham, J., Bédard, P. J., Bartoszyk, G. D., & Paolo, T. D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.11.001 · Cited by 98
Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements
Cao, X., Yasuda, T., Uthayathas, S., Watts, R. L., Mouradian, M. M., Mochizuki, H., & Papa, S. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0252-10.2010 · Cited by 96
Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel)
Postma, J. U., & van Tilburg, W. (1975) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1975.tb00187.x · Cited by 96
Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Hodgson, R. A., Bédard, P. J., Varty, G. B., Kazdoba, T. M., Paolo, T. D., Grzelak, M. E., Pond, A. J., Tahar, A. H., Bélanger, N., Grégoire, L., et al. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.011 · Cited by 95
Cerebral vasocapacitance and TIAs
Levine, R. L., Lagrèze, H. L., Dobkin, J. A., Hanson, J. M., Satter, M., Rowe, B. R., & Nickles, R. J. (1989) · Neurology · doi:10.1212/wnl.39.1.25 · Cited by 95
Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTPγ[S]binding to pertussis toxin
Clark, E. A., & Hill, S. J. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00800-4 · Cited by 95
Apomorphine responses in parkinson's disease and the pathogenesis of motor complications
Metman, L. V., Locatelli, E. R., Bravi, D., Mouradian, M. M., & Chase, T. N. (1997) · Neurology · doi:10.1212/wnl.48.2.369 · Cited by 95
Schuster, S., Nadjar, A., Guo, J. T., Li, Q., Ittrich, C., Hengerer, B., & Bézard, E. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4720-07.2008 · Cited by 95
Visanji, N. P., Fox, S. H., Johnston, T. H., Reyes, G., Millan, M. J., & Brotchie, J. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.010 · Cited by 95
Self-citationKannari, K., Kurahashi, K., Tomiyama, M., Maeda, T., Arai, A., Baba, M., Suda, T., & Matsunaga, M. (2002) · PubMed · Cited by 95
Nash, J. E., Ravenscroft, P., McGuire, S., Crossman, A. R., Menniti, F. S., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.004 · Cited by 94
Self-citationCalon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00237-8 · Cited by 93
Identification of A2a Adenosine Receptor Domains Involved in Selective Coupling to GS
Olah, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.337 · Cited by 92
Herrero, M. T., Lévy, R., Ruberg, M., Luquín, M. R., Villares, J., López-Guillén, J. L., Faucheux, B. A., Javoy-Agid, F., Guridi, J., Agid, Y., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.219 · Cited by 92
Watts, R., Lyons, K., Pahwa, R., Sethi, K., Stern, M., Hauser, R. A., Olanow, W., Gray, A., Adams, B. E., & Earl, N. (2010) · Movement Disorders · doi:10.1002/mds.22890 · Cited by 92
Schuster, S., Doudnikoff, É., Ottosson, D. R., Berthet, A., Aubert, I., Ittrich, C., Bloch, B., Cenci, M. A., Surmeier, D. J., Hengerer, B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.008 · Cited by 92
Hanrieder, J., Ljungdahl, A., Fälth, M., Mammo, S. E., Bergquist, J., & Andersson, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.009308 · Cited by 92
Grégoire, L., Rassoulpour, A., GUIDETTI, P., Samadi, P., BEDARD, P., Izzo, E., Schwarcz, R. M., & Paolo, T. D. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.08.007 · Cited by 91
Maratos, E. C., Jackson, M. J., Pearce, R. K. B., & Jenner, P. G. (2001) · Movement Disorders · doi:10.1002/mds.1149 · Cited by 91
Onset and End-of-Dose Levodopa-Induced Dyskinesias
Lhermitte, F. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500290007002 · Cited by 91
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease
Jenner, P. G. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s1 · Cited by 91
Guigoni, C., Li, Q., Aubert, I., Doveró, S., Bioulac, B. H., Bloch, B., Crossman, A. R., Gross, C. E., & Bézard, E. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.5059-04.2005 · Cited by 91
Nash, J. E., & Brotchie, J. M. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-20-07782.2000 · Cited by 90
Self-citationZolpidem in Parkinson's disease
Daniele, A., Albanese, A., Gainotti, G., Gregori, B., & Bartolomeo, P. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62416-6 · Cited by 89
Newman‐Tancredi, A. (2011) · Neuropsychiatry · doi:10.2217/npy.11.12 · Cited by 89
Bishop, C., Krolewski, D. M., Jaunarajs, K. L. E., Barnum, C. J., Dupre, K. B., Deak, T., & Walker, P. D. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21978 · Cited by 89
Lindgren, H. S., Ohlin, K. E., & Cenci, M. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.74 · Cited by 87
Continuous dopaminergic stimulation in early and advanced Parkinson’s disease
Stocchi, F., & Olanow, C. W. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s56 · Cited by 87
SNARE proteins mediate lipid bilayer fusion
Bock, J. B., & Scheller, R. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12227 · Cited by 86
Smith, L. A., Jackson, M. J., Hansard, M. J., Maratos, E. C., & Jenner, P. G. (2003) · Movement Disorders · doi:10.1002/mds.10394 · Cited by 86
Aubert, I., Guigoni, C., Li, Q., Doveró, S., Bioulac, B. H., Gross, C. E., Crossman, A. R., Bloch, B., & Bézard, E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.038 · Cited by 85
Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M., & Brotchie, J. M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1171-11.2011 · Cited by 85
Self-citationPicconi, B. (2002) · Brain · doi:10.1093/brain/awf269 · Cited by 84
Dupre, K. B., Jaunarajs, K. L. E., Negron, G. E., & Bishop, C. (2007) · Brain Research · doi:10.1016/j.brainres.2007.05.005 · Cited by 84
Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients
Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., Stanzione, P., Pisani, A., & Maccarrone, M. (2010) · Movement Disorders · doi:10.1002/mds.23014 · Cited by 84
Calcium-Channel Blockers for Hypertension — Uncertainty Continues
Cutler, J. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381009 · Cited by 84
Parkinson Study Group (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1660 · Cited by 84
A trial of dextromethorphan in parkinsonian patients with motor response complications
Metman, L. V., Blanchet, P. J., van den Munckhof, P., Dotto, P. D., Natté, R., & Chase, T. N. (1998) · Movement Disorders · doi:10.1002/mds.870130307 · Cited by 83
Grafe, M. R., Forno, L. S., & Eng, L. F. (1985) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198501000-00004 · Cited by 83
Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization
Bordia, T., Campos, C., McIntosh, J. M., & Quik, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162396 · Cited by 82 · cited 2×
“Following the unexpected discovery that chronic therapy with either nicotinic agonists or antagonists alleviates LID, it was proposed that nicotine alleviated dyskinesia after a desensitization phenomenon that would occur upon chronic administration (Bordia et al., 2010).”
BackgroundComparative Review of Dopamine Receptor Agonists in Parkinsonʼs Disease
Uitti, R. J., & Ahlskog, J. E. (1996) · CNS Drugs · doi:10.2165/00023210-199605050-00006 · Cited by 82
Rascol, O., Fabre, N., Blin, O. J., Poulik, J. M., Sabatini, U., Sénard, J., Ané, M., Montastruc, J., & Rascol, A. (1994) · Movement Disorders · doi:10.1002/mds.870090410 · Cited by 82
Nadjar, A., Brotchie, J. M., Guigoni, C., Li, Q., Zhou, S., Wang, G.-J., Ravenscroft, P., Georges, F. E., Crossman, A. R., & Bézard, E. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2582-06.2006 · Cited by 82
Self-citationGuigoni, C., Doveró, S., Aubert, I., Li, Q., Bioulac, B. H., Bloch, B., Gurevich, E. V., Gross, C. E., & Bézard, E. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04196.x · Cited by 82
Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., & Brotchie, J. M. (2001) · Movement Disorders · doi:10.1002/mds.1148 · Cited by 82
Self-citationArai, R., Karasawa, N., & Nagatsu, I. (1996) · Brain Research · doi:10.1016/0006-8993(95)01281-8 · Cited by 81
MK801 suppresses the l-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats
Jonkers, N., Sarre, S., Ebinger, G., & Michotte, Y. M. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03147-x · Cited by 81
Serum Renin Levels and Postnephrectomy Blood Pressure
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196907312810518 · Cited by 81
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Blanchet, P. J., Fang, J., Gillespie, M., Sabounjian, L., Locke, K. W., Gammans, R. E., Mouradian, M. M., & Chase, T. N. (1998) · PubMed · Cited by 79
Zeng, B. ‐., Dass, B., Owen, A., Rose, S., Cannizzaro, C., Tel, B. C., & Jenner, P. G. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00762-4 · Cited by 79
Brooks, D. J., Piccini, P. P., Turjanski, N., & Samuel, M. (2000) · PubMed · Cited by 78
Yoneda, Y., Tokui, K., Hanihara, T., Kitagaki, H., Tabuchi, M., & Mori, E. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199906)45:6<736::aid-ana7>3.0.co;2-f · Cited by 78
Vanover, K. E., Betz, A. J., WEBER, S., Bibbiani, F., Kielaitė, A., Weiner, D. M., DAVIS, R., Chase, T. N., & Salamone, J. D. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.04.010 · Cited by 78
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
Gardoni, F., Sgobio, C., Pendolino, V., Calabresi, P., Luca, M. D., & Picconi, B. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.019 · Cited by 78
Graham, W. C., Sambrook, M. A., & Crossman, A. R. (1993) · Brain Research · doi:10.1016/0006-8993(93)90694-i · Cited by 77
Cited by
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Self-citationCilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Metadata
- Authors
- Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 65
- Issue
- 1
- Pages
- 171-222
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2107758668
- Cited by
- 324
- References
- 558
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.